• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早产儿视网膜病变临床试验结果背后的实验证据。

Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.

作者信息

Hartnett Mary Elizabeth, Toth Cynthia Ann

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):228-234. doi: 10.3928/23258160-20190401-05.

DOI:10.3928/23258160-20190401-05
PMID:30998244
Abstract

Treatment of severe retinopathy of prematurity (ROP) has evolved over the last decade. This article reviews recent clinical trials and experimental evidence that supports clinical outcomes and observations, including the efficacy of anti-vascular endothelial growth factor (VEGF) agents in reducing the vascular activity of severe ROP, and the mechanisms behind recurrent stage 3 ROP and plus disease in some infants treated with anti-VEGF agents. Also discussed will be current imaging modalities that link experimental models of ROP with longitudinal human studies and which provide exciting future opportunities to enhance the understanding of pathophysiology of ROP and improve treatments. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:228-234.].

摘要

在过去十年中,早产儿视网膜病变(ROP)的治疗方法不断发展。本文回顾了近期支持临床结果和观察的临床试验及实验证据,包括抗血管内皮生长因子(VEGF)药物在降低重度ROP血管活性方面的疗效,以及接受抗VEGF药物治疗的部分婴儿出现复发性3期ROP和Plus病变背后的机制。还将讨论当前将ROP实验模型与纵向人体研究联系起来的成像方式,这些成像方式为加深对ROP病理生理学的理解和改进治疗方法提供了令人兴奋的未来机会。[《眼科手术、激光与视网膜成像》。2019年;50:228 - 234。]

相似文献

1
Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.早产儿视网膜病变临床试验结果背后的实验证据。
Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):228-234. doi: 10.3928/23258160-20190401-05.
2
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.用于治疗早产儿视网膜病变的抗血管内皮生长因子(VEGF)药物。
Cochrane Database Syst Rev. 2016;2:CD009734. doi: 10.1002/14651858.CD009734.pub2. Epub 2016 Feb 27.
3
Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity.双侧玻璃体内注射贝伐单抗后,一名早产儿发生双侧玻璃体出血。
Ophthalmic Surg Lasers Imaging Retina. 2018 Nov 1;49(11):893-896. doi: 10.3928/23258160-20181101-11.
4
Playing With Fire.玩火。
Ophthalmic Surg Lasers Imaging Retina. 2020 Oct 1;51(10):542-544. doi: 10.3928/23258160-20201005-01.
5
The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.0.16mg 贝伐单抗联合或不联合额外激光光凝治疗早产儿视网膜病变的安全性和有效性。
Indian J Ophthalmol. 2019 Jun;67(6):879-883. doi: 10.4103/ijo.IJO_2115_18.
6
Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab.贝伐单抗治疗三年后早产儿视网膜病变复发
Ophthalmic Surg Lasers Imaging Retina. 2017 Mar 1;48(3):255-259. doi: 10.3928/23258160-20170301-10.
7
Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection.抗血管内皮生长因子注射后复发性早产儿视网膜病变的管理
J Pediatr Ophthalmol Strabismus. 2019 Mar 19;56(2):68-70. doi: 10.3928/01913913-20181220-01.
8
A Surgical Technique for the Management of Tractional Retinal Detachment in Aggressive Posterior Retinopathy of Prematurity Treated With Intravitreal Bevacizumab.一种用于治疗接受玻璃体内贝伐单抗治疗的侵袭性早产儿视网膜病变所致牵引性视网膜脱离的手术技术。
Retina. 2019 Oct;39 Suppl 1:S156-S159. doi: 10.1097/IAE.0000000000002304.
9
Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.玻璃体内注射贝伐单抗或激光治疗 1 型 ROP 后 4 年的功能和形态学发现。
Ophthalmic Surg Lasers Imaging Retina. 2020 Mar 1;51(3):180-186. doi: 10.3928/23258160-20200228-07.
10
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.1 型早产儿视网膜病变玻璃体腔内注射贝伐单抗与激光治疗的 4 年随访:荧光血管造影结果。
Ophthalmology. 2018 Feb;125(2):218-226. doi: 10.1016/j.ophtha.2017.08.005. Epub 2017 Sep 1.

引用本文的文献

1
Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity.激光与抗血管内皮生长因子:治疗性早产儿视网膜病变的范式转变
Ophthalmol Ther. 2023 Oct;12(5):2241-2252. doi: 10.1007/s40123-023-00744-7. Epub 2023 Jun 19.
2
Staged lensectomy and vitrectomy in the management of stage 5C retinopathy of prematurity with corneal opacification: long-term follow up.分期晶状体切除术和玻璃体切除术治疗伴有角膜混浊的5C期早产儿视网膜病变:长期随访
Int J Ophthalmol. 2022 Sep 18;15(9):1437-1443. doi: 10.18240/ijo.2022.09.05. eCollection 2022.
3
The benefits, limitations and opportunities of preclinical models for neonatal drug development.
新生儿药物开发的临床前模型的优势、局限性和机遇。
Dis Model Mech. 2022 Apr 1;15(4). doi: 10.1242/dmm.049065. Epub 2022 Apr 25.
4
Macular OCT Characteristics at 36 Weeks' Postmenstrual Age in Infants Examined for Retinopathy of Prematurity.早产儿视网膜病变筛查婴儿在 36 孕周时的黄斑 OCT 特征。
Ophthalmol Retina. 2021 Jun;5(6):580-592. doi: 10.1016/j.oret.2020.09.004. Epub 2020 Sep 11.